Literature DB >> 6090293

The persistence of hepatitis A IgM antibody after acute clinical hepatitis A.

H W Kao, M Ashcavai, A G Redeker.   

Abstract

Hepatitis A IgM antibody (IgM anti-HAV), detected by commercially available solid-phase radioimmunoassay, is an accepted marker of acute viral hepatitis A infection. However, persistence of this serological marker far beyond the acute illness and immediate convalescent period has been reported. To determine the persistence of IgM anti-HAV following clinically manifest acute hepatitis A infection, 59 patients with this diagnosis were followed prospectively until this marker disappeared or persisted for greater than 60 days. Timed from the onset of jaundice, IgM anti-HAV persisted for less than 30 to greater than 420 days; most patients became seronegative by 120 days. These findings suggest that some patients may become seronegative early in the disease course while others (13.5%) remain positive for prolonged periods greater than 200 days. Awareness of this marked variability is important in the interpretation of IgM anti-HAV as a serologic marker of recent hepatitis A infection.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6090293     DOI: 10.1002/hep.1840040525

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  14 in total

Review 1.  Diagnosis of hepatitis a virus infection: a molecular approach.

Authors:  Omana V Nainan; Guoliang Xia; Gilberto Vaughan; Harold S Margolis
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

2.  Prevalence of anti-HAV antibodies in multitransfused patients with beta-thalassemia.

Authors:  Dimitrios Siagris; Alexandra Kouraklis-Symeonidis; Irini Konstantinidou; Myrto Christofidou; Ioannis Starakis; Alexandra Lekkou; Christos Papadimitriou; Alexandros Blikas; Nicholas Zoumbos; Chryssoula Labropoulou-Karatza
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

Review 3.  Hepatitis A: old and new.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

4.  New Subgenotyping and Consensus Real-Time Reverse Transcription-PCR Assays for Hepatitis A Outbreak Surveillance.

Authors:  William S Probert; Jill K Hacker
Journal:  J Clin Microbiol       Date:  2019-08-26       Impact factor: 5.948

5.  Nosocomial hepatitis A infection in a paediatric intensive care unit.

Authors:  L M Drusin; M Sohmer; S L Groshen; M D Spiritos; L B Senterfit; W N Christenson
Journal:  Arch Dis Child       Date:  1987-07       Impact factor: 3.791

6.  Seroprevalence and Molecular Characterisation of Human Hepatitis A virus in Serum Samples of Tunisian Patients with Clinical Symptoms of Viral Hepatitis.

Authors:  Hakima Gharbi-Khelifi; Nabil Ben Salem Abid; Abir Beji; Leila Bhiri; Rafik Harrath; Khira Sdiri; Sylviane Billaudel; Virginie Ferre; Mahjoub Aouni
Journal:  Indian J Virol       Date:  2012-03-25

7.  Appearance and persistence of hepatitis A IgM antibody in acute clinical hepatitis A observed in an outbreak.

Authors:  Y F Liaw; C Y Yang; C M Chu; M J Huang
Journal:  Infection       Date:  1986 Jul-Aug       Impact factor: 3.553

8.  Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020.

Authors:  Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris
Journal:  MMWR Recomm Rep       Date:  2020-07-03

9.  Optimal time for repeating the IgM anti-hepatitis A virus antibody test in acute hepatitis A patients with a negative initial test.

Authors:  Jong Jin Hyun; Yeon Seok Seo; Hyonggin An; Sun Young Yim; Min Ho Seo; Hye Sook Kim; Chang Ha Kim; Ji Hoon Kim; Bora Keum; Yong Sik Kim; Hyung Joon Yim; Hong Sik Lee; Soon Ho Um; Chang Duck Kim; Ho Sang Ryu
Journal:  Korean J Hepatol       Date:  2012-03-22

10.  Epidemiology of hepatitis A virus infections, Germany, 2007-2008.

Authors:  Mirko S Faber; Klaus Stark; Susanne C Behnke; Eckart Schreier; Christina Frank
Journal:  Emerg Infect Dis       Date:  2009-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.